Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis

PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis. We present results from our first clinical study of PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF). This 12-week open-label study...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalil, Nasreen, Manganas, Helene, Ryerson, Christopher J., Shapera, Shane, Cantin, Andre M., Hernandez, Paul, Turcotte, Eric E., Parker, Joseph M., Moran, John E., Albert, Gary R., Sawtell, Renata, Hagerimana, Aline, Laurin, Pierre, Gagnon, Lyne, Cesari, Frank, Kolb, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422836/
https://www.ncbi.nlm.nih.gov/pubmed/30578394
http://dx.doi.org/10.1183/13993003.00663-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422836/
https://www.ncbi.nlm.nih.gov/pubmed/30578394
http://dx.doi.org/10.1183/13993003.00663-2018

Ejemplares similares